Holen Sie sich die Stockscreener-App
10.09
7.42%
-0.82
Schlusskurs vom Vortag:
$10.91
Offen:
$11
24-Stunden-Volumen:
270.41K
Relative Volume:
0.79
Marktkapitalisierung:
$544.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-5.07%
1M Leistung:
+4.61%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.03
$11.37
1-Wochen-Bereich:
$10.11
$11.50
52-Wochen-Spanne:
$7.90
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Firmenname
Eikon Therapeutics Inc
Sektor
Branche
Telefon
341-777-0566
Adresse
230 HARRIET TUBMAN WAY, MILLBRAE
Compare EIKN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
10.05 | 590.65M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
436.52 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.88 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.13 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.74 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.40 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Eingeleitet | BofA Securities | Buy |
| 2026-03-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-02 | Eingeleitet | Mizuho | Outperform |
| 2026-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-02-26 | Eingeleitet | Wedbush | Underperform |
Alle ansehen
Eikon Therapeutics Inc Aktie (EIKN) Neueste Nachrichten
Eikon to present clinical data on three cancer programs at ASCO - Investing.com UK
Eikon Therapeutics to present six abstracts on cancer drug trials at 2026 ASCO meeting - Pluang
Eikon Therapeutics Announces Presentation of Advanced Clinical Data at 2026 ASCO Annual Meeting - Quiver Quantitative
Eikon Therapeutics Announces Availability of Six Abstracts - GlobeNewswire
EIKN SEC FilingsEikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace
Number of shareholders of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Innovation Endeavors reports 3.37M shares in Eikon Therapeutics (EIKN) - Stock Titan
BofA Securities Maintains Eikon Therapeutics(EIKN.US) With Buy Rating, Maintains Target Price $34 - Moomoo
EIKN Should I Buy - Intellectia AI
Roger Perlmutter holds 2.89M shares of Eikon Therapeutics (NASDAQ: EIKN) - Stock Titan
Eikon Therapeutics, Inc.Common Stock (Nasdaq:EIKN) Stock Quote - FinancialContent
Wedbush Maintains Eikon Therapeutics(EIKN.US) With Sell Rating, Cuts Target Price to $5 - Moomoo
Wedbush Cuts Price Target on Eikon Therapeutics to $5 From $7, Keeps Underperform Rating - marketscreener.com
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates - Sahm
Eikon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
IPO cash lifts Eikon Therapeutics (NASDAQ: EIKN) to $596M - Stock Titan
Eikon Therapeutics (Nasdaq: EIKN) details Q1 loss and ASCO 2026 data plans - Stock Titan
Press Release: Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates - Moomoo
FMR LLC holds 3.84M EIKON Therapeutics shares (NASDAQ: EIKN) - Stock Titan
Eikon Therapeutics prices upsized IPO at $18 per share By Investing.com - Investing.com Nigeria
[SCHEDULE 13G] Eikon Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Merck reportedly eyeing $30M stake in Eikon Therapeutics’ IPO - MSN
Merck veteran-led Eikon seeks $908M valuation in US IPO - MSN
Should I be cautious with Eikon Therapeutics (EIKN) stock today (Market Focus) 2026-04-20Most Discussed Stocks - Xã Châu Thành
ETFs Investing in Eikon Therapeutics, Inc. Stocks - TradingView
EIKN: Eikon Therapeutics, Inc.Comparison to Industry - Zacks Investment Research
All News for EIKN : Eikon Therapeutics, Inc. - Zacks Investment Research
EIKN : Eikon Therapeutics, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
Eikon Therapeutics, Inc. News — NASDAQ:EIKN - TradingView
EIKN Forecast — Price Target — Prediction for 2027 - TradingView
Diluted shares outstanding of Eikon Therapeutics, Inc. – BX:EIKN - TradingView — Track All Markets
Number of employees of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Eikon Therapeutics, Inc. Statistics – BX:EIKN - TradingView — Track All Markets
EIKN Price Today: Eikon Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
IPO market strengthens in Q1 2026 as biopharma financings reach $22.82B - BioWorld News
Should I buy Eikon Therapeutics, Inc. (EIKN) - Zacks Investment Research
EIKN Analyst Rating Reiterated at Underperform by Wedbush | EIKN Stock News - GuruFocus
Eikon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Mizuho reiterates Eikon Therapeutics stock rating on pipeline update By Investing.com - Investing.com Canada
Mizuho reiterates Eikon Therapeutics stock rating on pipeline update - Investing.com
IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace
Eikon Therapeutics Reports 2025 Financial Results, Upsized IPO, and Key Clinical Pipeline Progress - Minichart
Eikon Therapeutics Reports Q4 and Full Year 2025 Results, Provides Clinical Updates - National Today
Finanzdaten der Eikon Therapeutics Inc-Aktie (EIKN)
Es liegen keine Finanzdaten für Eikon Therapeutics Inc (EIKN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):